212 related articles for article (PubMed ID: 16570106)
1. Contribution of CB1 blockade to the management of high-risk abdominal obesity.
Després JP; Lemieux I; Alméras N
Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S44-52. PubMed ID: 16570106
[TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease.
Després JP
J Endocrinol Invest; 2006; 29(3 Suppl):77-82. PubMed ID: 16751711
[TBL] [Abstract][Full Text] [Related]
3. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease under the influence of excess visceral fat.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoid system and cardiometabolic risk.
Saavedra LE
Clin Pharmacol Ther; 2007 Nov; 82(5):591-4. PubMed ID: 17898706
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
7. The endocannabinoid system as a novel approach for managing obesity.
Lillo JL
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.
Aronne LJ; Isoldi KK
Am J Cardiol; 2007 Dec; 100(12A):18P-26P. PubMed ID: 18154742
[TBL] [Abstract][Full Text] [Related]
9. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
11. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
12. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
13. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology?
Lemieux I; Poirier P; Bergeron J; Alméras N; Lamarche B; Cantin B; Dagenais GR; Després JP
Can J Cardiol; 2007 Oct; 23 Suppl B(Suppl B):23B-31B. PubMed ID: 17932584
[TBL] [Abstract][Full Text] [Related]
14. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
[TBL] [Abstract][Full Text] [Related]
15. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.
Rosenson RS
Cardiology; 2009; 114(3):212-25. PubMed ID: 19641317
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of cannabinoid receptors and glucose metabolism.
Scheen AJ; Paquot N
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
[TBL] [Abstract][Full Text] [Related]
17. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
[TBL] [Abstract][Full Text] [Related]
18. The endocannabinoid system: a new approach to control cardiovascular disease.
Cannon CP
Clin Cornerstone; 2005; 7(2-3):17-26. PubMed ID: 16473257
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid-1 receptor antagonists in type-2 diabetes.
Scheen AJ
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
[TBL] [Abstract][Full Text] [Related]
20. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
Cox SL
Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
